CORRECTION article

Front. Pharmacol., 26 July 2023

Sec. Pharmacology of Anti-Cancer Drugs

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1256801

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report

  • Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Article metrics

View details

1

Citations

1k

Views

388

Downloads

In the published article, the names in the Author list were incorrectly written as “Ning Yan*†, Si Huang, Lin Li, Qian Guo, Di Geng, Hui Zhang, San Guo* and Xing Li*.” The correct spelling is “Ningning Yan*†, Siyuan Huang, Linlin Li, Qianqian Guo, Di Geng, Huixian Zhang, Sanxing Guo* and Xingya Li*.” The updated Author Contributions statement appears below.

“All authors participated in the diagnosis and treatment process. NY, SH, and XL diagnosed the patient and developed the treatment plan. NY, SH, LL, QG, DG, and HZ participated in the follow-up course. NY, SH, SG, and XL wrote the original manuscript. All authors contributed to the article and approved the submitted version.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

immune checkpoint inhibitor, NSCLC, ROS1, chemo-immunotherapy, lung adenocarcinoma

Citation

Yan N, Huang S, Li L, Guo Q, Geng D, Zhang H, Guo S and Li X (2023) Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report. Front. Pharmacol. 14:1256801. doi: 10.3389/fphar.2023.1256801

Received

20 July 2023

Accepted

21 July 2023

Published

26 July 2023

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

14 - 2023

Updates

Copyright

*Correspondence: Ningning Yan, ; Xingya Li, ; Sanxing Guo,

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics